ArkVax Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ArkVax Limited - overview
Established
2020
Location
Cambridge, -, UK
Primary Industry
Biotechnology
About
Founded in 2020 by Brenden Wren and Jon Cuccui, and based in Cambridge, UK, ArkVax Limited was formed as a spinoff from the London School of Hygiene & Tropical Medicine (LSHTM) and operates as a biotechnology company that develops vaccines for protecting animals and cattle various bacterial diseases. In December 2022, new investor Start Codon raise an undisclosed amount of seed funding for ArkVax Limited. ArkVax is a vaccine candidate development company that researches and develops vaccines and tests them directly in target animals to protect animals against various diseases. The firm uses technology to develop recombinant glycoconjugate vaccines in bacterial cells to help animals fight diseases and produce more milk/eggs.
The company intends to use the December 2022 funding to hire more teams and further develop its vaccine platform technology.
Current Investors
Start Codon
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Verticals
Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.